Updated results from a rapcabtagene autoleucel (YTB323) phase I study demonstrate durable efficacy and a manageable safety profile in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

The updated results from a phase 1 trial—originally presented during the 2023 Annual Meeting of the Society of Hematologic Oncology—of patients with relapsed/refractory DLBCL show that next-generation, autologous CD19-directed CAR T-cell therapy rapcabtagene autoleucel has promising durable efficacy and a manageable safety profile.